Atyr Pharma Inc

Research Atyr Pharma Inc (ATYR) on Bullrun: market cap USD 55.91M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 55.91M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 190.00K-USD 74.12M-USD 62.06Mn/a-0.8USD 10.74MUSD 12.03MUSD 67.48M
FY2024USD 235.00K-USD 64.02M-USD 69.18Mn/a-0.86USD 11.06MUSD 13.28MUSD 70.02M
FY2023USD 353.00K-USD 50.39M-USD 37.44Mn/a-0.94USD 22.54MUSD 15.10MUSD 90.66M
FY2022USD 10.39M-USD 45.34M-USD 43.53Mn/a-1.6USD 9.98Mn/aUSD 71.46M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 55.91Mn/an/an/a
20252025-12-31USD 76.46Mn/an/an/a
20242024-12-31USD 304.22Mn/an/an/a
20232023-12-29USD 82.57Mn/an/an/a
20222022-12-30USD 63.53Mn/an/an/a
20212021-12-31USD 207.61Mn/an/an/a

About Atyr Pharma Inc

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs);

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Atyr Pharma Inc's market cap?

Atyr Pharma Inc's market capitalization is USD 55.91M.

What does Atyr Pharma Inc do?

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.